An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Trial ID or NCT#
Status
Purpose
The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy
Official Title
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Eligibility Criteria
- * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1* Histologically confirmed Stage IV, or Recurrent NSCLC with no prior systemic anticancer therapy* Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid tumors version (RECIST) 1.1 criteria* PD-L1+ on immunohistochemistry testing performed by central lab* Men and women, ages ≥ 18 years of age
- * Known epidermal growth factor receptor (EGFR) mutations which are sensitive to available targeted inhibitor therapy* Known anaplastic lymphoma kinase (ALK) translocations* Untreated central nervous system (CNS) metastases* Previous malignancies* Active, known or suspected autoimmune disease
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
CCTO
650-498-7061
View on ClinicalTrials.gov